MarketInOut Stock Screener Log In | Sign Up
 

PDS Biotechnology Corp

NASDAQ • Healthcare • Biotechnology • Quote as of 10/23/2026
PDS Biotechnology Corp stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization91.77 mln
Float55.00 mln
Earnings Date11/12/2026

Piotroski F-Score

2 / 9
Weak

1-Year Forecast

5.00
Transformational upside

Relative Strength

13 / 100
Significantly lagging

ROE

-481
Deeply negative

ROA

-121
Deeply negative

Business Description

PDS Biotechnology is a Princeton-based clinical-stage company focused on developing new treatments for cancer and infectious diseases. Its most advanced therapy, Versamune HPV, is currently in Phase II trials targeting several HPV-related cancers, including head and neck, cervical, and anal cancers. The company also has a range of earlier-stage programs aimed at conditions such as leukemia, breast cancer, and ovarian cancer, alongside a novel flu vaccine. PDS Biotechnology works with partners including the National Institutes of Health and Merck to advance its research.

Key Fundamentals

EPS-0.64
ROE-481
ROIC-279
ROA-121
Interest Cover-4.18
EBITDA, mln-26.95
EV / EBITDA-1.45
EV / EBIT-1.45

Quote Details

Last 1.11
Change -0.05 (-4.31%)
Open 1.11
Volume 2,649,061
Turnover 2,940,458
Average Volume 11,175,092

Financial Strength

Piotroski F-Score 2 / 9
1-Year Target Price5.00
Short Ratio0.05
Short % of Float3.93

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -1.77% 29 / 100   
1 Month 38.73% 99 / 100   
2 Months 54.75% 98 / 100   
6 Months 23.26% 90 / 100   
1 Year 18.73% 78 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog